Clinical trials: Adults With Overweight and Obesity, active
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity and Obesity-related Medical Conditions
Efficacy and Safety of Tirzepatide for Weight Management
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes.
- Trial name
- NCT06918405
- Testing
- Tirzepatide
- Where
- Bangladesh
- Volunteers
- 440 people
- Sponsor
- Chittagong Medical College
Overweight and Obese Adults, High Intensity Interval Exercise (HIIE)
Acute Effects of Isoenergetic HIIE vs. MICE on Key Parameters of Fat Mass Loss in Young Females With Overweight or Obesity
Overweight and obesity, particularly increased total and/or abdominal fat mass (FM), are strongly linked to the development of cardiovascular diseases.
- Trial name
- COMEFIT (NCT06868862)
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
Obesity, Type 2 Diabetes
Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")
The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions Magnet System, GJ Biofragmentable ("MagGJ System") for creation of a side-to-side anastomosis for gastro-ileal or…
- Trial name
- NCT06073457
- Testing
- MagGJ System
- Where
- 4 sites in Canada, Chile and 2 more
- Volunteers
- 35 people
- Sponsor
- GT Metabolic Solutions, Inc.
Overweight, Obesity
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in…
- Conditions
- Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
- Trial name
- SOLIS-1 (NCT07575932)
- Testing
- PF-08653945, PF-08653944
- Where
- 63 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Pfizer
Overweight and/or Obesity, Metabolic Syndrome
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
This randomized, sham-controlled trial evaluates the efficacy and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight…
- Conditions
- Overweight and/or Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
- Trial name
- iWAIST-RCT (NCT07237750)
- Testing
- Endoscopic Radial Compression Gastroplasty, Optimized Lifestyle Intervention (OLI)
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Liu Yan
Metabolic Syndrome, Insulin Resistance
EFFECTS OF OLEUROPEIN ON BLOOD PARAMETERS AND INFLAMMATORY MARKERS IN ADULTS WITH METABOLIC SYNDROME
The aim of this study is to determine the effect of 6 weeks supplementation of oleuropein on individuals diagnosed with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Insulin Resistance, Obesity, Abdominal, Obesity
- Trial name
- NCT06673914
- Testing
- Control Group: Diet Group, Oleuropein and Diet Group
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Atlas University
Obesity
Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance
This study investigates how weight-loss medications, specifically GLP-1 receptor agonists, affect body composition, with a special focus on preserving muscle mass in adults with obesity.
- Trial name
- LEAN-PRO GLP-1 (NCT07495904)
- Testing
- High Protein Dietary Intervention, Control (Standard Mediterranean Diet Counseling)
- Where
- 2 sites in Greece
- Volunteers
- 130 people
- Sponsor
- Hellenic Mediterranean University
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss…
- Trial name
- RESTORE (NCT05819853)
- Testing
- Semaglutide Injectable Product (Wegovy and/or Ozempic)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Alcohol Use Disorder (AUD), Overweight or Obese
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight/obesity (AUD-OOB) to receive either a sub-cutaneous injection of…
- Conditions
- Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
- Trial name
- NCT07292519
- Testing
- Tirzepatide, Take Control CBT Module
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- South West Sydney Local Health District
Obesity, Metabolic Syndrome
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly…
- Conditions
- Obesity, Metabolic Syndrome, Brown Adipose Tissue
- Trial name
- BAT-Sema (NCT07621640)
- Testing
- Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulation, Liver MRI (PDFF + MRE)
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Hallym University
Obesity & Overweight
A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
The goal of this clinical trial is to determine whether a semaglutide dose-tapering regimen is non-inferior to a treatment-dose maintenance regimen for weight-loss maintenance in adults with overweight or obesity who have…
- Trial name
- NCT07783854
- Testing
- Semaglutide Dose-Tapering Regimen, Semaglutide Maintenance-Dose Regimen
- Volunteers
- 72 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Dyslipidemias, Obesity
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.
- Trial name
- NCT05700916
- Testing
- Milk Polar Lipid-Rich Dairy Powder, Dairy Powder
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Obesity & Overweight
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity.
- Trial name
- NCT07622810
- Testing
- Bofanglutida, Semaglutide
- Where
- 6 sites in Mexico
- Volunteers
- 352 people
- Sponsor
- Carnot Laboratories
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Trial name
- ENLIGHTEN-1 (NCT07321886)
- Testing
- Eloralintide
- Where
- 158 sites in United States, Argentina and 13 more
- Volunteers
- 1,980 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity.
- Conditions
- Obesity, Overweight, Osteoarthritis of the Knee
- Trial name
- NCT07919678
- Testing
- Berobenatide
- Where
- 40 sites in United States, Canada
- Volunteers
- 656 people
- Sponsor
- Pfizer